Cancer/Tumors Clinical Trials

A listing of Cancer/Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

, progression-free survival (PFS) and response rate (RR). SAMPLE:Patients must have a histologically confirmed diagnosis of epithelial ovarian cancer, cancer of the Fallopian tube or primary

paclitaxel
platinum-sensitive ovarian carcinoma
ovarian epithelial cancer
gemcitabine
cancer antigen 125
  • 10 views
  • 07 Nov, 2020
  • 1 location
Evaluation Glizigen and Ocoxin -Viusid in High-grade Cervical Intraepithelial Lesions

Phase II clinical trial, monocentric, not controlled, in patients with high grade cervical intraepithelial lesions. A total of 62 patients with a diagnosis of CIN II, III or carcinoma in situ will be included. It is expected that with the combination of natural products Glizigen and Ocoxin-Viusid at least 60% …

colposcopy
ocoxin
cervical intraepithelial neoplasia grade 2
vasectomy
carcinoma
  • 19 views
  • 27 Jan, 2021
  • 1 location
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

The purpose of this phase II trial is to determine the feasibility and efficacy of nimotuzumab combined with concurrent chemoradiotherapy for initially inoperable locally advanced cervical squamous cell carcinoma.

EGFR
calcium
external beam radiation therapy
squamous cell carcinoma
cancer
  • 14 views
  • 22 Jan, 2021
  • 1 location
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

PARP inhibitors have changed the treatment paradigm of ovarian cancer. Most patients using PARP(poly-ADP ribose polymerase) inhibitors will suffer different grades of adverse events(AEs), followed by dose reduction. It has not been reported whether the dose-reduced olaparib as maintenance treatment have an impact on efficacy. Both PAOLA-1 and AVANOVA 2 …

ovarian cancer
fallopian tube
RET
primary cancer
ejection fraction
  • 5 views
  • 27 Jan, 2021
  • 1 location
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits tumor angiogenesis and is also recommended for the treatment of recurrent ovarian cancer. Clinical …

ovarian cancer
cancer antigen 125
platelet count
parp inhibitor
fallopian tube
  • 0 views
  • 26 Jan, 2021
  • 1 location
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy. This study evaluates whether or not the addition of simvastatin to the dual anti-HER2 therapy regimen helps make the tumor respond to the anti-HER2 therapy again. All participants will receive simvastatin …

breast cancer
HER2
metastasis
hormone therapy
ejection fraction
  • 6 views
  • 24 Jan, 2021
  • 2 locations
Nivolumab Ipilimumab and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and …

bicalutamide
epidermal growth factor
breast cancer
her2/neu-negative breast cancer
cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk …

  • 0 views
  • 27 Jan, 2021
  • 1 location